Assessing the response of morphea and limited scleroderma to tranilast: a small prospective study comparing topical corticosteroids to a combination of topical corticosteroids and tranilast
Rowland Noakes Queensland Institute of Dermatology, Greenslopes Private Hospital Campus, Greenslopes, QLD, Australia Background: Scleroderma is traditionally managed with immunomodulatory agents such as methotrexate, mycophenolate mofetil and corticosteroids. There are anecdotal reports for, and the...
Main Author: | Noakes R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-07-01
|
Series: | Clinical, Cosmetic and Investigational Dermatology |
Subjects: | |
Online Access: | https://www.dovepress.com/assessing-the-response-of-morphea-and-limited-scleroderma-to-tranilast-peer-reviewed-article-CCID |
Similar Items
-
Anti-cancer effects of Tranilast: An update
by: Soha Osman, et al.
Published: (2021-09-01) -
Antioxidant and Hepatoprotective Effects of Tranilast against Thioacetamide-Induced Liver Fibrosis in Rats
by: Ramadan A., et al.
Published: (2017-10-01) -
Effects of tranilast on the epithelial-to-mesenchymal transition in peritoneal mesothelial cells
by: Seok Hui Kang, et al.
Published: (2019-12-01) -
Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
by: Yi Huang, et al.
Published: (2018-04-01) -
Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles
by: Misa Minami, et al.
Published: (2020-04-01)